首页 > 最新文献

中南大学学报(医学版)最新文献

英文 中文
[Application progress of single-cell RNA sequencing technology in breast development and related diseases]. [单细胞RNA测序技术在乳腺发育及相关疾病中的应用进展]。
Q3 Medicine Pub Date : 2025-06-28 DOI: 10.11817/j.issn.1672-7347.2025.250039
Shiyi Wen, Yang Hu, Xiangyu Chen, Jianda Zhou, Ping Li

The spatio-temporal heterogeneity of breast cell subsets forms the fundamental biological basis for physiological development and pathological progression, including tumorigenesis; however, its complex regulatory mechanisms are not yet fully elucidated. With its high-resolution capabilities, single-cell RNA sequencing (scRNA-seq) technology offers a powerful tool for dissecting this cellular heterogeneity. This technology enables the construction of high-precision breast cell atlases, the accurate identification of distinct cell subsets, and the reconstruction of differentiation trajectories from stem/progenitor cells to functional epithelial cells. By resolving the transcriptional regulatory networks that govern cell fate determination, intercellular communication patterns, and dynamic microenvironmental interactions, scRNA-seq has unveiled the molecular foundations of breast development and provided new perspectives on the pathogenesis of related diseases such as breast cancer and macromastia. Furthermore, scRNA-seq demonstrates significant potential for discovering early molecular markers of disease, deciphering tumor heterogeneity, and elucidating mechanisms of therapeutic resistance. The continued application of scRNA-seq for dissecting breast cell heterogeneity, combined with its integration with multi-modal data such as spatial omics, promises to provide critical evidence and new insights for revealing the molecular mechanisms of breast development-related diseases and for formulating precision therapeutic strategies.

乳腺细胞亚群的时空异质性构成了包括肿瘤发生在内的生理发育和病理进展的基本生物学基础;然而,其复杂的调控机制尚未完全阐明。凭借其高分辨率的能力,单细胞RNA测序(scRNA-seq)技术为解剖这种细胞异质性提供了强大的工具。该技术能够构建高精度的乳腺细胞图谱,准确识别不同的细胞亚群,并重建从干细胞/祖细胞到功能性上皮细胞的分化轨迹。通过解析控制细胞命运决定、细胞间通讯模式和动态微环境相互作用的转录调控网络,scRNA-seq揭示了乳房发育的分子基础,并为乳腺癌和巨乳症等相关疾病的发病机制提供了新的视角。此外,scRNA-seq在发现疾病的早期分子标记、破译肿瘤异质性和阐明治疗耐药机制方面显示出巨大的潜力。scRNA-seq在剖析乳腺细胞异质性方面的持续应用,结合其与空间组学等多模态数据的整合,有望为揭示乳腺发育相关疾病的分子机制和制定精确的治疗策略提供关键证据和新的见解。
{"title":"[Application progress of single-cell RNA sequencing technology in breast development and related diseases].","authors":"Shiyi Wen, Yang Hu, Xiangyu Chen, Jianda Zhou, Ping Li","doi":"10.11817/j.issn.1672-7347.2025.250039","DOIUrl":"10.11817/j.issn.1672-7347.2025.250039","url":null,"abstract":"<p><p>The spatio-temporal heterogeneity of breast cell subsets forms the fundamental biological basis for physiological development and pathological progression, including tumorigenesis; however, its complex regulatory mechanisms are not yet fully elucidated. With its high-resolution capabilities, single-cell RNA sequencing (scRNA-seq) technology offers a powerful tool for dissecting this cellular heterogeneity. This technology enables the construction of high-precision breast cell atlases, the accurate identification of distinct cell subsets, and the reconstruction of differentiation trajectories from stem/progenitor cells to functional epithelial cells. By resolving the transcriptional regulatory networks that govern cell fate determination, intercellular communication patterns, and dynamic microenvironmental interactions, scRNA-seq has unveiled the molecular foundations of breast development and provided new perspectives on the pathogenesis of related diseases such as breast cancer and macromastia. Furthermore, scRNA-seq demonstrates significant potential for discovering early molecular markers of disease, deciphering tumor heterogeneity, and elucidating mechanisms of therapeutic resistance. The continued application of scRNA-seq for dissecting breast cell heterogeneity, combined with its integration with multi-modal data such as spatial omics, promises to provide critical evidence and new insights for revealing the molecular mechanisms of breast development-related diseases and for formulating precision therapeutic strategies.</p>","PeriodicalId":39801,"journal":{"name":"中南大学学报(医学版)","volume":"50 6","pages":"1080-1087"},"PeriodicalIF":0.0,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12464921/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145182299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Therapeutic effects of natural products on animal models of chronic obstructive pulmonary disease]. [天然产物对慢性阻塞性肺疾病动物模型的治疗作用]
Q3 Medicine Pub Date : 2025-06-28 DOI: 10.11817/j.issn.1672-7347.2025.240124
Xinru Fei, Guixian Yang, Junnan Liu, Tong Liu, Wei Gao, Dongkai Zhao

Chronic obstructive pulmonary disease (COPD) currently lacks effective treatments to halt disease progression, making the search for preventive and therapeutic drugs a pressing issue. Natural products, with their accessibility, affordability, and low toxicity, offer promising avenues. Investigating the pharmacological effects and related signaling mechanisms of active components from natural products on COPD animal models induced by various triggers has become an important focus. In animal models induced by cigarette smoke, cigarette smoke combined with lipopolysaccharide (LPS), air pollution, elastase, bacterial or viral infections, the active compounds of natural products, such as flavonoids, terpenoids, and phenolics, can exert anti-inflammatory, antioxidant, mucus-regulating, and airway remodeling-inhibiting effects through key signaling pathways including nuclear factor-erythroid 2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1), nuclear factor-kappa B (NF-κB), and mitogen-activated protein kinase (MAPK). These findings not only provide a theoretical basis for the clinical diagnosis and treatment of COPD but also point to new directions for future scientific research.

慢性阻塞性肺疾病(COPD)目前缺乏有效的治疗方法来阻止疾病的进展,因此寻找预防和治疗药物成为一个紧迫的问题。天然产品,以其可及性、可负担性和低毒性,提供了有希望的途径。研究天然产物活性成分对各种诱发因素诱导的COPD动物模型的药理作用及相关信号机制已成为一个重要的研究热点。在香烟烟雾诱导的动物模型中,香烟烟雾与脂多糖(LPS)、空气污染、弹性酶、细菌或病毒感染联合作用,其天然产物黄酮类、萜类、酚类物质等活性化合物可通过核因子-红细胞2相关因子2 (Nrf2)/血红素加氧酶-1 (HO-1)、核因子-κB (NF-κB)等关键信号通路发挥抗炎、抗氧化、调节粘液、抑制气道重塑等作用。和丝裂原活化蛋白激酶(MAPK)。这些发现不仅为慢性阻塞性肺病的临床诊断和治疗提供了理论依据,也为今后的科学研究指明了新的方向。
{"title":"[Therapeutic effects of natural products on animal models of chronic obstructive pulmonary disease].","authors":"Xinru Fei, Guixian Yang, Junnan Liu, Tong Liu, Wei Gao, Dongkai Zhao","doi":"10.11817/j.issn.1672-7347.2025.240124","DOIUrl":"10.11817/j.issn.1672-7347.2025.240124","url":null,"abstract":"<p><p>Chronic obstructive pulmonary disease (COPD) currently lacks effective treatments to halt disease progression, making the search for preventive and therapeutic drugs a pressing issue. Natural products, with their accessibility, affordability, and low toxicity, offer promising avenues. Investigating the pharmacological effects and related signaling mechanisms of active components from natural products on COPD animal models induced by various triggers has become an important focus. In animal models induced by cigarette smoke, cigarette smoke combined with lipopolysaccharide (LPS), air pollution, elastase, bacterial or viral infections, the active compounds of natural products, such as flavonoids, terpenoids, and phenolics, can exert anti-inflammatory, antioxidant, mucus-regulating, and airway remodeling-inhibiting effects through key signaling pathways including nuclear factor-erythroid 2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1), nuclear factor-kappa B (NF-κB), and mitogen-activated protein kinase (MAPK). These findings not only provide a theoretical basis for the clinical diagnosis and treatment of COPD but also point to new directions for future scientific research.</p>","PeriodicalId":39801,"journal":{"name":"中南大学学报(医学版)","volume":"50 6","pages":"1067-1079"},"PeriodicalIF":0.0,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12464926/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145182298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Establishment and application of a UPLC-MS/MS method for the determination of tiletamine and its metabolite in biological samples]. [生物样品中替乐胺及其代谢物的UPLC-MS/MS测定方法的建立与应用]。
Q3 Medicine Pub Date : 2025-06-28 DOI: 10.11817/j.issn.1672-7347.2025.240609
Zihao Cai, Wenguang Yan, Jiahao Li, Yanjun Ding, Jiang Ling
<p><strong>Objectives: </strong>Tiletamine, a veterinary anesthetic, has emerged as a novel psychoactive substance and has been abused in many parts of the world, causing great harm to public health. However, the sensitivity of existing detection methods cannot meet the needs of forensic practice. This study aims to establish an ultra-high-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method for the determination of tiletamine and its metabolite desethyltiletamine in human biological samples, and to verify its applicability in forensic practice.</p><p><strong>Methods: </strong>SKF<sub>525A</sub> was used as the internal standard. Biological samples were extracted with acetonitrile containing 1 ng/mL SKF<sub>525A</sub>, vortexed for 10 min, ultrasonicated for 20 min, centrifuged at 10 000 r/min for 10 min, and 500 μL of the supernatant was filtered through a 0.22 μm membrane. Analyses were performed using an ACQUITY UPLC H-Class PLUS system and an XEVO TQ-S Micro triple quadrupole mass spectrometer. An ACQUITY UPLC<sup>®</sup> BEH C18 (1.7 µm, 2.1 mm×100 mm) column at a flow rate of 0.3 mL/min was used, and four mobile phase systems were tested to optimize separation. Detection used positive electrospray ionization (ESI+) in multiple reaction monitoring (MRM) mode, with quantifier ion transitions of mass to charge 224.043→179.016 for tiletamine and mass to charge 196.08→151.06 for desethyltiletamine. Calibration curves were established over 0.1-200 ng/mL in spiked blood samples. The linear range, limit of detection (LOD), and limit of quantification (LOQ) were determined. Low (5 ng/mL), medium (20 ng/mL), and high (100 ng/mL) concentrations of tiletamine were spiked into blood, liver, and kidney to evaluate precision, accuracy, matrix effect, recovery, and stability. Finally, actual forensic case samples were tested to validate applicability.</p><p><strong>Results: </strong>The established UPLC-MS/MS method achieved simultaneous detection of tiletamine and desethyltiletamine in human biological samples, with retention times of 3.42 min and 2.82 min, respectively. Using mobile phase A (20 mmol/L ammonium acetate and 0.1% formic acid in water) and mobile phase B (acetonitrile) produced the best separation. In blood, tiletamine showed good linearity from 0.1-200 ng/mL (<i>r</i>=0.992, <i>R</i><sup>2</sup>=0.983), LOD 0.03 ng/mL, LOQ 0.1 ng/mL, recovery 92%-107%, and matrix effect 71%-99%. In liver and kidney, recoveries were 91%-98% and 93%-104%, and matrix effects were 69%-96% and 72%-100%, respectively. Intra- and inter-day precision [expressed as relative standard deviation (RSD)] and accuracy [expressed as relative error (RE)] were within 15%, and samples were stable at -20 ℃. Tiletamine was detected in actual case samples at 0.37 μg/mL (blood), 0.15 μg/g (liver), 0.11 μg/g (kidney) in case 1, and 8.75 ng/mL (blood) in case 2; desethyltiletamine was also detected in blood.</p><p><strong>Conclusions: </strong>The UPLC-MS/
目的:替乐胺是一种兽药,是一种新型精神活性物质,在世界许多地方被滥用,对公众健康造成极大危害。然而,现有的检测方法的灵敏度不能满足法医实践的需要。本研究旨在建立一种超高效液相色谱-串联质谱(UPLC-MS/MS)测定人体生物样品中替乐胺及其代谢物去乙基替乐胺的方法,并验证其在法医实践中的适用性。方法:以SKF525A为内标。生物样品用含有1 ng/mL SKF525A的乙腈提取,旋涡10 min,超声20 min, 10000 r/min离心10 min, 0.22 μm膜过滤500 μL上清。使用ACQUITY UPLC H-Class PLUS系统和XEVO TQ-S Micro三重四极杆质谱仪进行分析。采用ACQUITY UPLC®BEH C18(1.7µm, 2.1 mm×100 mm)色谱柱,流速为0.3 mL/min,采用四种流动相体系进行分离优化。检测采用多反应监测(MRM)模式下的正电喷雾电离(ESI+),对替乐胺的定量离子跃迁为质量电荷224.043→179.016,对去乙基替乐胺的定量离子跃迁为质量电荷196.08→151.06。在0.1 ~ 200 ng/mL范围内建立校正曲线。确定了该方法的线性范围、检出限和定量限。将低浓度(5ng /mL)、中浓度(20ng /mL)和高浓度(100ng /mL)的替乐胺加入血液、肝脏和肾脏中,以评估精密度、准确度、基质效应、回收率和稳定性。最后,对实际法医案例样本进行了测试,以验证其适用性。结果:建立的UPLC-MS/MS方法可同时检测人体生物样品中的替乐胺和去乙基替乐胺,保留时间分别为3.42 min和2.82 min。采用流动相A (20 mmol/L乙酸铵和0.1%甲酸水溶液)和流动相B(乙腈)分离效果最佳。在血液中,替乐胺在0.1 ~ 200 ng/mL范围内呈良好的线性关系(r=0.992, R2=0.983),检出限0.03 ng/mL,检出限0.1 ng/mL,回收率92% ~ 107%,基质效应71% ~ 99%。在肝脏和肾脏中,加样回收率分别为91% ~ 98%和93% ~ 104%,基质效应分别为69% ~ 96%和72% ~ 100%。日内、日间精密度[以相对标准偏差(RSD)表示]和准确度[以相对误差(RE)表示]均在15%以内,样品在-20℃下稳定。实际病例标本中tilletamine的检测值分别为0.37 μg/mL(血)、0.15 μg/g(肝)、0.11 μg/g(肾)、8.75 ng/mL(血);血液中也检测到去乙基替乐胺。结论:UPLC-MS/MS方法高效、准确、灵敏,适用于人体生物样品中替乐胺和去乙基替乐胺的检测。
{"title":"[Establishment and application of a UPLC-MS/MS method for the determination of tiletamine and its metabolite in biological samples].","authors":"Zihao Cai, Wenguang Yan, Jiahao Li, Yanjun Ding, Jiang Ling","doi":"10.11817/j.issn.1672-7347.2025.240609","DOIUrl":"10.11817/j.issn.1672-7347.2025.240609","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objectives: &lt;/strong&gt;Tiletamine, a veterinary anesthetic, has emerged as a novel psychoactive substance and has been abused in many parts of the world, causing great harm to public health. However, the sensitivity of existing detection methods cannot meet the needs of forensic practice. This study aims to establish an ultra-high-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method for the determination of tiletamine and its metabolite desethyltiletamine in human biological samples, and to verify its applicability in forensic practice.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;SKF&lt;sub&gt;525A&lt;/sub&gt; was used as the internal standard. Biological samples were extracted with acetonitrile containing 1 ng/mL SKF&lt;sub&gt;525A&lt;/sub&gt;, vortexed for 10 min, ultrasonicated for 20 min, centrifuged at 10 000 r/min for 10 min, and 500 μL of the supernatant was filtered through a 0.22 μm membrane. Analyses were performed using an ACQUITY UPLC H-Class PLUS system and an XEVO TQ-S Micro triple quadrupole mass spectrometer. An ACQUITY UPLC&lt;sup&gt;®&lt;/sup&gt; BEH C18 (1.7 µm, 2.1 mm×100 mm) column at a flow rate of 0.3 mL/min was used, and four mobile phase systems were tested to optimize separation. Detection used positive electrospray ionization (ESI+) in multiple reaction monitoring (MRM) mode, with quantifier ion transitions of mass to charge 224.043→179.016 for tiletamine and mass to charge 196.08→151.06 for desethyltiletamine. Calibration curves were established over 0.1-200 ng/mL in spiked blood samples. The linear range, limit of detection (LOD), and limit of quantification (LOQ) were determined. Low (5 ng/mL), medium (20 ng/mL), and high (100 ng/mL) concentrations of tiletamine were spiked into blood, liver, and kidney to evaluate precision, accuracy, matrix effect, recovery, and stability. Finally, actual forensic case samples were tested to validate applicability.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The established UPLC-MS/MS method achieved simultaneous detection of tiletamine and desethyltiletamine in human biological samples, with retention times of 3.42 min and 2.82 min, respectively. Using mobile phase A (20 mmol/L ammonium acetate and 0.1% formic acid in water) and mobile phase B (acetonitrile) produced the best separation. In blood, tiletamine showed good linearity from 0.1-200 ng/mL (&lt;i&gt;r&lt;/i&gt;=0.992, &lt;i&gt;R&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt;=0.983), LOD 0.03 ng/mL, LOQ 0.1 ng/mL, recovery 92%-107%, and matrix effect 71%-99%. In liver and kidney, recoveries were 91%-98% and 93%-104%, and matrix effects were 69%-96% and 72%-100%, respectively. Intra- and inter-day precision [expressed as relative standard deviation (RSD)] and accuracy [expressed as relative error (RE)] were within 15%, and samples were stable at -20 ℃. Tiletamine was detected in actual case samples at 0.37 μg/mL (blood), 0.15 μg/g (liver), 0.11 μg/g (kidney) in case 1, and 8.75 ng/mL (blood) in case 2; desethyltiletamine was also detected in blood.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;The UPLC-MS/","PeriodicalId":39801,"journal":{"name":"中南大学学报(医学版)","volume":"50 6","pages":"1002-1012"},"PeriodicalIF":0.0,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12464931/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145182311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gender differences in the burden of near vision loss in China: An analysis based on GBD 2021 data. 中国近视力丧失负担的性别差异:基于GBD 2021数据的分析
Q3 Medicine Pub Date : 2025-06-28 DOI: 10.11817/j.issn.1672-7347.2025.240710
Yu Liu, Liping Zhu, Yanhui Lin, Yanbing Wang, Kun Xiong, Xuhong Li, Wenguang Yan

Objectives: Near vision loss (NVL) is one of the leading causes of visual impairment worldwide, exerting a profound impact on individual quality of life and socio-economic development. This study aims to analyze the burden of NVL in China by sex and age groups from 1990 to 2021 and to project trends over the next 15 years.

Methods: Using data from the Global Burden of Disease (GBD) 2021 database, we conducted descriptive analyses of NVL prevalence in China, calculated age-standardized prevalence rates (ASPR) and age-standardized disability-adjusted life years rates (ASDR) to compare burden differences between sexes and age groups, and applied an autoregressive integrated moving average (ARIMA) model to predict NVL trends for the next 15 years. The model selection was based on best-fit criteria to ensure reliable projections.

Results: From 1990 to 2021, China's ASPR of NVL rose from 10 096.24/100 000 to 15 624.54/100 000, and ASDR increased from 101.75/100 000 to 158.75/100 000. In 2021, ASPR (16 551.70/100 000) and ASDR (167.69/100 000) were higher among females than males (14 686.21/100 000 and 149.76/100 000, respectively). China ranked highest globally in both NVL cases and disability-adjusted life years (DALYs), with female burden significantly exceeding male burden. Projections indicated this trend and sex gap will persist until 2036. Compared with 1990, the prevalence cases and DALYs increased by 239.20% and 238.82%, respectively in 2021, with the highest burden among females and the 55-59 age group. The ARIMA model predicted continued increases in prevalence and DALYs by 2036, with females maintaining a higher burden than males.

Conclusions: This study reveals a marked increase in the NVL burden in China and predicts continued growth in the coming years. Public health policies should prioritize NVL prevention and control, with special attention to women and middle-aged populations to mitigate long-term societal and health impacts.

目的:近视力丧失(NVL)是世界范围内视力损害的主要原因之一,对个人生活质量和社会经济发展产生深远影响。本研究旨在分析1990年至2021年中国按性别和年龄组划分的非机动车负担,并预测未来15年的趋势。方法:利用全球疾病负担(GBD) 2021数据库的数据,对中国NVL患病率进行描述性分析,计算年龄标准化患病率(ASPR)和年龄标准化残疾调整生命年率(ASDR),比较性别和年龄组之间的负担差异,并应用自回归综合移动平均(ARIMA)模型预测未来15年NVL趋势。模型选择基于最佳拟合标准,以确保可靠的预测。结果:1990 - 2021年,中国NVL的ASPR从10 096.24/10万上升到15 624.54/10万,ASDR从101.75/10万上升到158.75/10万。2021年女性的ASPR(16 551.70/10万)和ASDR(167.69/10万)分别高于男性(14 686.21/10万和149.76/10万)。中国在NVL病例和残疾调整生命年(DALYs)方面均居全球首位,女性负担明显超过男性负担。预测显示,这一趋势和性别差距将持续到2036年。与1990年相比,2021年的患病率和DALYs分别增加了239.20%和238.82%,其中女性和55-59岁年龄组负担最重。ARIMA模型预测,到2036年,患病率和DALYs将继续增加,女性的负担将高于男性。结论:本研究揭示了中国NVL负担的显著增加,并预测未来几年将继续增长。公共卫生政策应优先考虑NVL的预防和控制,特别关注妇女和中年人口,以减轻长期的社会和健康影响。
{"title":"Gender differences in the burden of near vision loss in China: An analysis based on GBD 2021 data.","authors":"Yu Liu, Liping Zhu, Yanhui Lin, Yanbing Wang, Kun Xiong, Xuhong Li, Wenguang Yan","doi":"10.11817/j.issn.1672-7347.2025.240710","DOIUrl":"10.11817/j.issn.1672-7347.2025.240710","url":null,"abstract":"<p><strong>Objectives: </strong>Near vision loss (NVL) is one of the leading causes of visual impairment worldwide, exerting a profound impact on individual quality of life and socio-economic development. This study aims to analyze the burden of NVL in China by sex and age groups from 1990 to 2021 and to project trends over the next 15 years.</p><p><strong>Methods: </strong>Using data from the Global Burden of Disease (GBD) 2021 database, we conducted descriptive analyses of NVL prevalence in China, calculated age-standardized prevalence rates (ASPR) and age-standardized disability-adjusted life years rates (ASDR) to compare burden differences between sexes and age groups, and applied an autoregressive integrated moving average (ARIMA) model to predict NVL trends for the next 15 years. The model selection was based on best-fit criteria to ensure reliable projections.</p><p><strong>Results: </strong>From 1990 to 2021, China's ASPR of NVL rose from 10 096.24/100 000 to 15 624.54/100 000, and ASDR increased from 101.75/100 000 to 158.75/100 000. In 2021, ASPR (16 551.70/100 000) and ASDR (167.69/100 000) were higher among females than males (14 686.21/100 000 and 149.76/100 000, respectively). China ranked highest globally in both NVL cases and disability-adjusted life years (DALYs), with female burden significantly exceeding male burden. Projections indicated this trend and sex gap will persist until 2036. Compared with 1990, the prevalence cases and DALYs increased by 239.20% and 238.82%, respectively in 2021, with the highest burden among females and the 55-59 age group. The ARIMA model predicted continued increases in prevalence and DALYs by 2036, with females maintaining a higher burden than males.</p><p><strong>Conclusions: </strong>This study reveals a marked increase in the NVL burden in China and predicts continued growth in the coming years. Public health policies should prioritize NVL prevention and control, with special attention to women and middle-aged populations to mitigate long-term societal and health impacts.</p>","PeriodicalId":39801,"journal":{"name":"中南大学学报(医学版)","volume":"50 6","pages":"1030-1041"},"PeriodicalIF":0.0,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12464932/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145182397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Association between stigma and quality of life in community-dwelling patients with schizophrenia: Multiple mediating roles of anxiety and depression symptoms]. 社区精神分裂症患者的病耻感与生活质量的关系:焦虑和抑郁症状的多重中介作用。
Q3 Medicine Pub Date : 2025-06-28 DOI: 10.11817/j.issn.1672-7347.2025.250138
Yue Chen, Xiaoyan Wan, Qin Yang, Changjiu He, Xuanyi Hu, Xiang Liu, Yuanyuan Liu

Objectives: Stigma is common among community-dwelling patients with schizophrenia and has a profound negative impact on both psychiatric symptoms and quality of life. This study aims to explore the association between stigma and quality of life in this population and to examine the multiple mediating roles of anxiety and depression symptoms.

Methods: The multi-stage stratified cluster random sampling method was used to select the community-dwelling patients with schizophrenics in Chengdu, Sichuan Province, China. The questionnaire included general demographic characteristics, stigma question, the Generalized Anxiety Disorder-7 (GAD-7) scale, the Patient Health Questionnaire-9 (PHQ-9), and the 12-item Short Form Health Survey (SF-12). The SF-12 was used to measure quality of life, including physical health and mental health dimensions. A multiple mediation model was used to analyse the mediating effects of anxiety and depression symptoms together between stigma and quality of life.

Results: A total of 1 087 community patients with schizophrenia were included with a mean age of 50.68±12.73 years; 525 (48.30%) were male. Stigma was reported by 543 patients (49.95%). Anxiety symptoms were present in 292 patients (26.86%), and depression symptoms in 407 patients (37.44%). The physical health quality of life score was 72.01 ± 20.99, and the mental health quality of life score was 71.68 ± 19.38. Multiple mediation analysis showed that stigma directly affected quality of life, and also indirectly affected quality of life through anxiety and depression symptoms. Anxiety and depression jointly mediated 42.26% of the total effect of stigma on physical health quality of life and 47.51% on mental health quality of life.

Conclusions: Reducing stigma and preventing anxiety and depression symptoms in community-dwelling patients with schizophrenia can effectively improve their quality of life and support reintegration into society.

目的:耻辱感在社区精神分裂症患者中很常见,对精神症状和生活质量都有深远的负面影响。本研究旨在探讨耻辱感与该人群生活质量之间的关系,并研究焦虑和抑郁症状的多重中介作用。方法:采用多阶段分层整群随机抽样方法,对四川省成都市社区精神分裂症患者进行抽样调查。问卷包括一般人口学特征、病耻感问题、广泛性焦虑障碍-7 (GAD-7)量表、患者健康问卷-9 (PHQ-9)和12项简短健康调查(SF-12)。SF-12用于测量生活质量,包括身体健康和心理健康两个维度。采用多重中介模型分析焦虑和抑郁症状在病耻感与生活质量之间的共同中介作用。结果:共纳入社区精神分裂症患者1 087例,平均年龄50.68±12.73岁;男性525例(48.30%)。543例(49.95%)患者出现病耻感。焦虑症状292例(26.86%),抑郁症状407例(37.44%)。生理健康生活质量得分为72.01±20.99分,心理健康生活质量得分为71.68±19.38分。多重中介分析显示,病耻感直接影响生活质量,并通过焦虑、抑郁症状间接影响生活质量。焦虑和抑郁共同介导病耻感对身体健康生活质量总影响的42.26%和对心理健康生活质量总影响的47.51%。结论:减少社区精神分裂症患者的耻辱感,预防其焦虑和抑郁症状,可有效提高其生活质量,为其重返社会提供支持。
{"title":"[Association between stigma and quality of life in community-dwelling patients with schizophrenia: Multiple mediating roles of anxiety and depression symptoms].","authors":"Yue Chen, Xiaoyan Wan, Qin Yang, Changjiu He, Xuanyi Hu, Xiang Liu, Yuanyuan Liu","doi":"10.11817/j.issn.1672-7347.2025.250138","DOIUrl":"10.11817/j.issn.1672-7347.2025.250138","url":null,"abstract":"<p><strong>Objectives: </strong>Stigma is common among community-dwelling patients with schizophrenia and has a profound negative impact on both psychiatric symptoms and quality of life. This study aims to explore the association between stigma and quality of life in this population and to examine the multiple mediating roles of anxiety and depression symptoms.</p><p><strong>Methods: </strong>The multi-stage stratified cluster random sampling method was used to select the community-dwelling patients with schizophrenics in Chengdu, Sichuan Province, China. The questionnaire included general demographic characteristics, stigma question, the Generalized Anxiety Disorder-7 (GAD-7) scale, the Patient Health Questionnaire-9 (PHQ-9), and the 12-item Short Form Health Survey (SF-12). The SF-12 was used to measure quality of life, including physical health and mental health dimensions. A multiple mediation model was used to analyse the mediating effects of anxiety and depression symptoms together between stigma and quality of life.</p><p><strong>Results: </strong>A total of 1 087 community patients with schizophrenia were included with a mean age of 50.68±12.73 years; 525 (48.30%) were male. Stigma was reported by 543 patients (49.95%). Anxiety symptoms were present in 292 patients (26.86%), and depression symptoms in 407 patients (37.44%). The physical health quality of life score was 72.01 ± 20.99, and the mental health quality of life score was 71.68 ± 19.38. Multiple mediation analysis showed that stigma directly affected quality of life, and also indirectly affected quality of life through anxiety and depression symptoms. Anxiety and depression jointly mediated 42.26% of the total effect of stigma on physical health quality of life and 47.51% on mental health quality of life.</p><p><strong>Conclusions: </strong>Reducing stigma and preventing anxiety and depression symptoms in community-dwelling patients with schizophrenia can effectively improve their quality of life and support reintegration into society.</p>","PeriodicalId":39801,"journal":{"name":"中南大学学报(医学版)","volume":"50 6","pages":"1042-1051"},"PeriodicalIF":0.0,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12464919/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145182321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Research progress on bioactive peptides in the treatment of oral diseases. 生物活性肽在口腔疾病治疗中的研究进展
Q3 Medicine Pub Date : 2025-05-28 DOI: 10.11817/j.issn.1672-7347.2025.240585
Weiman Huang, Yujing Wang, Xidi Wang, Kun Li

Peptide-based drugs possess several advantages, including high specificity, low immunogenicity, minimal accumulation, and fewer drug-drug interactions, making them a novel and efficient therapeutic class for various diseases. In recent years, peptide-based drugs have shown great potential and broad application prospects in the treatment of oral infectious diseases, tissue injury and repair, tumors, and complex oral mucosal disorders, acting either through direct mechanisms or indirect modulation. Oral administration remains the preferred route due to its non-invasive, painless nature and ease of management; however, gastrointestinal pH can inactivate or even degrade peptide drugs. In the treatment of oral diseases, local administration is commonly employed, avoiding gastrointestinal degradation and first-pass metabolism. Nevertheless, limitations in current theoretical research and the high cost of peptide synthesis hinder their clinical application. Future efforts should focus on advancing related studies to promote the practical application of peptide-based drugs in the field of oral medicine.

肽基药物具有特异性高、免疫原性低、积累少、药物相互作用少等优点,是治疗多种疾病的新型有效药物。近年来,肽类药物在口腔感染性疾病、组织损伤与修复、肿瘤及复杂口腔黏膜疾病的治疗中显示出巨大的潜力和广阔的应用前景,其作用机制或直接,或间接调节。由于其无创、无痛和易于管理,口服给药仍是首选途径;然而,胃肠道pH值可以使多肽药物失活甚至降解。在口腔疾病的治疗中,通常采用局部给药,避免胃肠道降解和首过代谢。然而,目前理论研究的局限性和肽合成的高成本阻碍了它们的临床应用。今后应重点推进相关研究,促进肽类药物在口腔医学领域的实际应用。
{"title":"Research progress on bioactive peptides in the treatment of oral diseases.","authors":"Weiman Huang, Yujing Wang, Xidi Wang, Kun Li","doi":"10.11817/j.issn.1672-7347.2025.240585","DOIUrl":"10.11817/j.issn.1672-7347.2025.240585","url":null,"abstract":"<p><p>Peptide-based drugs possess several advantages, including high specificity, low immunogenicity, minimal accumulation, and fewer drug-drug interactions, making them a novel and efficient therapeutic class for various diseases. In recent years, peptide-based drugs have shown great potential and broad application prospects in the treatment of oral infectious diseases, tissue injury and repair, tumors, and complex oral mucosal disorders, acting either through direct mechanisms or indirect modulation. Oral administration remains the preferred route due to its non-invasive, painless nature and ease of management; however, gastrointestinal pH can inactivate or even degrade peptide drugs. In the treatment of oral diseases, local administration is commonly employed, avoiding gastrointestinal degradation and first-pass metabolism. Nevertheless, limitations in current theoretical research and the high cost of peptide synthesis hinder their clinical application. Future efforts should focus on advancing related studies to promote the practical application of peptide-based drugs in the field of oral medicine.</p>","PeriodicalId":39801,"journal":{"name":"中南大学学报(医学版)","volume":"50 5","pages":"907-912"},"PeriodicalIF":0.0,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12406105/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145016446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Application of stereotactic radiotherapy in the treatment of cardiovascular diseases through sympathectomy. 立体定向放疗在交感神经切除术治疗心血管疾病中的应用。
Q3 Medicine Pub Date : 2025-05-28 DOI: 10.11817/j.issn.1672-7347.2025.240702
Zhangli Xie, Liyi Liao, Shuang Zhang, Lin Hu, Xuping Li

Sympathectomy, as an emerging treatment method for cardiovascular diseases, has received extensive attention in recent years. Stereotactic radiotherapy (SRT), a precise and noninvasive therapeutic technique, has gradually been introduced into interventions targeting the sympathetic nervous system and has shown promising prospects in the management of cardiovascular conditions. Using three-dimensional imaging, SRT can accurately localize sympathetic ganglia and deliver high-energy radiation to disrupt nerve fibers, thereby achieving effects similar to conventional sympathectomy while reducing surgery-related complications and shortening recovery time. It also offers the advantages of being noninvasive and causing fewer adverse effects, and thus holds potential as an alternative to traditional approaches in the future. The integration of SRT with sympathectomy opens new avenues for the treatment of cardiovascular diseases and presents broad clinical application prospects.

交感神经切除术作为一种新兴的心血管疾病治疗方法,近年来受到了广泛的关注。立体定向放射治疗(SRT)作为一种精确、无创的治疗技术,已逐渐被引入到针对交感神经系统的干预中,在心血管疾病的治疗中显示出良好的前景。SRT利用三维成像技术精确定位交感神经节,并给予高能辐射破坏神经纤维,达到与常规交感神经切除术相似的效果,同时减少手术相关并发症,缩短恢复时间。它还具有非侵入性和较少副作用的优点,因此在未来作为传统方法的替代方案具有潜力。SRT与交感神经切除术的结合为心血管疾病的治疗开辟了新的途径,具有广阔的临床应用前景。
{"title":"Application of stereotactic radiotherapy in the treatment of cardiovascular diseases through sympathectomy.","authors":"Zhangli Xie, Liyi Liao, Shuang Zhang, Lin Hu, Xuping Li","doi":"10.11817/j.issn.1672-7347.2025.240702","DOIUrl":"10.11817/j.issn.1672-7347.2025.240702","url":null,"abstract":"<p><p>Sympathectomy, as an emerging treatment method for cardiovascular diseases, has received extensive attention in recent years. Stereotactic radiotherapy (SRT), a precise and noninvasive therapeutic technique, has gradually been introduced into interventions targeting the sympathetic nervous system and has shown promising prospects in the management of cardiovascular conditions. Using three-dimensional imaging, SRT can accurately localize sympathetic ganglia and deliver high-energy radiation to disrupt nerve fibers, thereby achieving effects similar to conventional sympathectomy while reducing surgery-related complications and shortening recovery time. It also offers the advantages of being noninvasive and causing fewer adverse effects, and thus holds potential as an alternative to traditional approaches in the future. The integration of SRT with sympathectomy opens new avenues for the treatment of cardiovascular diseases and presents broad clinical application prospects.</p>","PeriodicalId":39801,"journal":{"name":"中南大学学报(医学版)","volume":"50 5","pages":"747-756"},"PeriodicalIF":0.0,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12406114/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145016501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
O-GlcNAcylated YTHDF2 promotes bladder cancer progression by regulating the tumor suppressor gene PER1 via m6A modification. o - glcn酰化的YTHDF2通过m6A修饰调节肿瘤抑制基因PER1促进膀胱癌进展。
Q3 Medicine Pub Date : 2025-05-28 DOI: 10.11817/j.issn.1672-7347.2025.250202
Li Wang, Da Ren, Zeqiang Cai, Wentao Hu, Yuting Chen, Xuan Zhu
<p><strong>Objectives: </strong>Bladder cancer is a common malignancy with high incidence and poor prognosis. N<sup>6</sup>-methyladenosine (m<sup>6</sup>A) modification is widely involved in diverse physiological processes, among which the m<sup>6</sup>A recognition protein YTH N<sup>6</sup>-methyladenosine RNA binding protein F2 (YTHDF2) plays a crucial role in bladder cancer progression. This study aims to elucidate the molecular mechanism by which O-linked <i>N</i>-acetylglucosamine (O-GlcNAc) modification of YTHDF2 regulates its downstream target, period circadian regulator 1 (<i>PER1</i>), thereby promoting bladder cancer cell proliferation.</p><p><strong>Methods: </strong>Expression of YTHDF2 in bladder cancer was predicted using The Cancer Genome Atlas (TCGA). Twenty paired bladder cancer and adjacent normal tissues were collected at the clinical level. Normal bladder epithelial cells (SV-HUC-1) and bladder cancer cell lines (T24, 5637, EJ-1, SW780, BIU-87) were examined by quantitative real-time PCR (RT-qPCR), Western blotting, and immunohistochemistry for expression of YTHDF2, PER1, and proliferation-related proteins [proliferating cell nuclear antigen (PCNA), minichromosome maintenance complex component 2 (MCM2), Cyclin D1]. <i>YTHDF2</i> was silenced in 5637 and SW780 cells, and cell proliferation was assessed by Cell Counting Kit-8 (CCK-8), colony formation, and EdU assays. Bioinformatics was used to predict glycosylation sites of YTHDF2, and immunoprecipitation (IP) was performed to detect O-GlcNAc modification levels of YTHDF2 in tissues and cells. Bladder cancer cells were treated with DMSO, OSMI-1 (O-GlcNAc inhibitor), or Thiamet G (O-GlcNAc activator), followed by cycloheximide (CHX), to assess YTHDF2 ubiquitination by IP. <i>YTHDF2</i> knockdown and Thiamet G treatment were further used to evaluate <i>PER1</i> mRNA stability, <i>PER1</i> m<sup>6</sup>A modification, and cell proliferation. TCGA was used to predict PER1 expression in tissues; SRAMP predicted potential PER1 m<sup>6</sup>A sites. Methylated RNA immunoprecipitation (MeRIP) assays measured PER1 m<sup>6</sup>A modification. Finally, the effects of knocking down <i>YTHDF2</i> and <i>PER1</i> on 5637 and SW780 cell proliferation were assessed.</p><p><strong>Results: </strong><i>YTHDF2</i> expression was significantly upregulated in bladder cancer tissues compared with adjacent tissues (mRNA: 2.5-fold; protein: 2-fold), which O-GlcNAc modification levels increased 3.5-fold (<i>P</i><0.001). YTHDF2 was upregulated in bladder cancer cell lines, and its knockdown suppressed cell viability (<i>P</i><0.001), downregulated PCNA, MCM2, and CyclinD1 (all <i>P</i><0.05), reduced colony numbers 3-fold (<i>P</i><0.01), and inhibited proliferation. YTHDF2 exhibited elevated O-GlcNAc modification in cancer cells. OSMI-1 reduced YTHDF2 protein stability (<i>P</i><0.01) and enhanced ubiquitination, while Thiamet G exerted opposite effects (<i>P</i><0.001). Thiamet G reversed the proli
目的:膀胱癌是一种常见的恶性肿瘤,发病率高,预后差。n6 -甲基腺苷(m6A)修饰广泛参与多种生理过程,其中m6A识别蛋白YTH n6 -甲基腺苷RNA结合蛋白F2 (YTHDF2)在膀胱癌进展中起着至关重要的作用。本研究旨在阐明O-linked N-acetylglucosamine (O-GlcNAc)修饰YTHDF2调控其下游靶点周期昼夜节律调节因子1 (period circadian regulator 1, PER1)从而促进膀胱癌细胞增殖的分子机制。方法:应用肿瘤基因组图谱(TCGA)预测YTHDF2在膀胱癌中的表达。临床收集20例膀胱癌配对及癌旁正常组织。采用实时荧光定量PCR (RT-qPCR)、Western blotting和免疫组化检测正常膀胱上皮细胞(SV-HUC-1)和膀胱癌细胞株(T24、5637、EJ-1、SW780、BIU-87) YTHDF2、PER1和增殖相关蛋白[增殖细胞核抗原(PCNA)、小染色体维持复合物组分2 (MCM2)、Cyclin D1]的表达。在5637和SW780细胞中沉默YTHDF2,通过细胞计数试剂盒-8 (CCK-8)、菌落形成和EdU检测评估细胞增殖。利用生物信息学预测YTHDF2的糖基化位点,利用免疫沉淀(IP)检测组织和细胞中YTHDF2的O-GlcNAc修饰水平。用DMSO、OSMI-1 (O-GlcNAc抑制剂)或Thiamet G (O-GlcNAc激活剂)处理膀胱癌细胞,然后用环己亚胺(CHX)处理,通过IP评估YTHDF2泛素化。YTHDF2敲除和Thiamet G处理进一步评估PER1 mRNA稳定性、PER1 m6A修饰和细胞增殖。采用TCGA预测PER1在组织中的表达;SRAMP预测潜在的PER1 m6A位点。甲基化RNA免疫沉淀(MeRIP)测定PER1 m6A修饰。最后,评估敲除YTHDF2和PER1对5637和SW780细胞增殖的影响。结果:膀胱癌组织中YTHDF2表达较癌旁组织明显上调(mRNA: 2.5倍;蛋白:2倍),其中O-GlcNAc修饰水平升高3.5倍(PPPPPPYTHDF2敲低,促进细胞增殖(PP6A识别,促进PER1 mRNA降解)。救援实验表明,PER1敲低逆转了YTHDF2敲低对细胞增殖的抑制作用,上调了PCNA、MCM2和Cyclin D1(均ppc)。结论:O-GlcNAc修饰YTHDF2通过m6a介导的转录后调控下调肿瘤抑制基因PER1,从而促进膀胱癌的发展。
{"title":"O-GlcNAcylated YTHDF2 promotes bladder cancer progression by regulating the tumor suppressor gene <i>PER1</i> via m<sup>6</sup>A modification.","authors":"Li Wang, Da Ren, Zeqiang Cai, Wentao Hu, Yuting Chen, Xuan Zhu","doi":"10.11817/j.issn.1672-7347.2025.250202","DOIUrl":"10.11817/j.issn.1672-7347.2025.250202","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objectives: &lt;/strong&gt;Bladder cancer is a common malignancy with high incidence and poor prognosis. N&lt;sup&gt;6&lt;/sup&gt;-methyladenosine (m&lt;sup&gt;6&lt;/sup&gt;A) modification is widely involved in diverse physiological processes, among which the m&lt;sup&gt;6&lt;/sup&gt;A recognition protein YTH N&lt;sup&gt;6&lt;/sup&gt;-methyladenosine RNA binding protein F2 (YTHDF2) plays a crucial role in bladder cancer progression. This study aims to elucidate the molecular mechanism by which O-linked &lt;i&gt;N&lt;/i&gt;-acetylglucosamine (O-GlcNAc) modification of YTHDF2 regulates its downstream target, period circadian regulator 1 (&lt;i&gt;PER1&lt;/i&gt;), thereby promoting bladder cancer cell proliferation.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Expression of YTHDF2 in bladder cancer was predicted using The Cancer Genome Atlas (TCGA). Twenty paired bladder cancer and adjacent normal tissues were collected at the clinical level. Normal bladder epithelial cells (SV-HUC-1) and bladder cancer cell lines (T24, 5637, EJ-1, SW780, BIU-87) were examined by quantitative real-time PCR (RT-qPCR), Western blotting, and immunohistochemistry for expression of YTHDF2, PER1, and proliferation-related proteins [proliferating cell nuclear antigen (PCNA), minichromosome maintenance complex component 2 (MCM2), Cyclin D1]. &lt;i&gt;YTHDF2&lt;/i&gt; was silenced in 5637 and SW780 cells, and cell proliferation was assessed by Cell Counting Kit-8 (CCK-8), colony formation, and EdU assays. Bioinformatics was used to predict glycosylation sites of YTHDF2, and immunoprecipitation (IP) was performed to detect O-GlcNAc modification levels of YTHDF2 in tissues and cells. Bladder cancer cells were treated with DMSO, OSMI-1 (O-GlcNAc inhibitor), or Thiamet G (O-GlcNAc activator), followed by cycloheximide (CHX), to assess YTHDF2 ubiquitination by IP. &lt;i&gt;YTHDF2&lt;/i&gt; knockdown and Thiamet G treatment were further used to evaluate &lt;i&gt;PER1&lt;/i&gt; mRNA stability, &lt;i&gt;PER1&lt;/i&gt; m&lt;sup&gt;6&lt;/sup&gt;A modification, and cell proliferation. TCGA was used to predict PER1 expression in tissues; SRAMP predicted potential PER1 m&lt;sup&gt;6&lt;/sup&gt;A sites. Methylated RNA immunoprecipitation (MeRIP) assays measured PER1 m&lt;sup&gt;6&lt;/sup&gt;A modification. Finally, the effects of knocking down &lt;i&gt;YTHDF2&lt;/i&gt; and &lt;i&gt;PER1&lt;/i&gt; on 5637 and SW780 cell proliferation were assessed.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;&lt;i&gt;YTHDF2&lt;/i&gt; expression was significantly upregulated in bladder cancer tissues compared with adjacent tissues (mRNA: 2.5-fold; protein: 2-fold), which O-GlcNAc modification levels increased 3.5-fold (&lt;i&gt;P&lt;/i&gt;&lt;0.001). YTHDF2 was upregulated in bladder cancer cell lines, and its knockdown suppressed cell viability (&lt;i&gt;P&lt;/i&gt;&lt;0.001), downregulated PCNA, MCM2, and CyclinD1 (all &lt;i&gt;P&lt;/i&gt;&lt;0.05), reduced colony numbers 3-fold (&lt;i&gt;P&lt;/i&gt;&lt;0.01), and inhibited proliferation. YTHDF2 exhibited elevated O-GlcNAc modification in cancer cells. OSMI-1 reduced YTHDF2 protein stability (&lt;i&gt;P&lt;/i&gt;&lt;0.01) and enhanced ubiquitination, while Thiamet G exerted opposite effects (&lt;i&gt;P&lt;/i&gt;&lt;0.001). Thiamet G reversed the proli","PeriodicalId":39801,"journal":{"name":"中南大学学报(医学版)","volume":"50 5","pages":"827-839"},"PeriodicalIF":0.0,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12406109/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145016427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Psychological experiences of young end stage renal disease patients awaiting kidney transplantation: A qualitative study. 年轻终末期肾病患者等待肾移植的心理体验:一项定性研究。
Q3 Medicine Pub Date : 2025-05-28 DOI: 10.11817/j.issn.1672-7347.2025.240554
Dian Liu, Huilan Xu, Zhihao Zhang, Liang Wang, Jia Liu, Xiao Zhu

Objectives: End stage renal disease (ESRD) is a major disease that seriously threatens the health of young people, and kidney transplantation is an effective treatment method to improve its prognosis.Young ESRD patients at a critical stage of life development often face significant physical and psychological challenges while waiting for kidney transplantation. Their psychological state directly affects treatment compliance and transplantation outcomes.This study aims to explore the psychological experiences of young patients with end stage renal disease during the waiting period for kidney transplantation, and provide a reference for formulating relevant psychological intervention measures.

Methods: A descriptive qualitative research design was adopted. Using purposive sampling, 20 young ESRD patients awaiting for kidney transplantation at the Transplantation Center of Xiangya Third Hospital, Central South University, from June to August 2024, were recruited. Based on the socio-ecological systems theory, a semi-structured interview outline was developed, and directed content analysis was applied to analyze the interview data.

Results: According to the results of qualitative interviews, 3 themes and 9 sub-themes were summarized as follows: Microsystem (disease pain experience, anxiety during transplantation waiting period, cognitive differentiation and coping differences), mesosystem (imbalance of family roles and dependent guilt, physician-patient trust dynamics, ambivalence toward peer support), and macrosystem (decision-making powerlessness caused by information asymmetry, sociocultural stigma and public bias, institutional dependence and passive behavior).

Conclusions: Young ESRD patients experience complex psychological experiences during the waiting period for kidney transplantation. Healthcare providers should explore corresponding intervention measures based on patients' psychological status to improve their waiting period experience and promote both physical and mental health.

目的:终末期肾病(End stage renal disease, ESRD)是严重威胁青少年健康的重大疾病,肾移植是改善其预后的有效治疗手段。处于生命发展关键阶段的年轻ESRD患者在等待肾移植时往往面临重大的生理和心理挑战。患者的心理状态直接影响治疗依从性和移植结果。本研究旨在探讨终末期肾病青年患者在肾移植候诊期的心理体验,为制定相关心理干预措施提供参考。方法:采用描述性定性研究设计。采用目的抽样方法,招募2024年6 - 8月在中南大学湘雅第三医院移植中心等待肾移植的年轻ESRD患者20例。基于社会生态系统理论,构建半结构化访谈提纲,并运用定向内容分析法对访谈数据进行分析。结果:根据定性访谈的结果,总结出3个主题和9个副主题如下:微观系统(疾病疼痛体验、移植等待期焦虑、认知分化和应对差异)、中观系统(家庭角色失衡和依赖内疚、医患信任动态、同伴支持矛盾心理)和宏观系统(信息不对称、社会文化污名和公众偏见、制度依赖和被动行为导致的决策无力)。结论:年轻ESRD患者在肾移植等待期经历复杂的心理体验。医疗服务提供者应根据患者的心理状况,探索相应的干预措施,改善患者的等待期体验,促进身心健康。
{"title":"Psychological experiences of young end stage renal disease patients awaiting kidney transplantation: A qualitative study.","authors":"Dian Liu, Huilan Xu, Zhihao Zhang, Liang Wang, Jia Liu, Xiao Zhu","doi":"10.11817/j.issn.1672-7347.2025.240554","DOIUrl":"10.11817/j.issn.1672-7347.2025.240554","url":null,"abstract":"<p><strong>Objectives: </strong>End stage renal disease (ESRD) is a major disease that seriously threatens the health of young people, and kidney transplantation is an effective treatment method to improve its prognosis.Young ESRD patients at a critical stage of life development often face significant physical and psychological challenges while waiting for kidney transplantation. Their psychological state directly affects treatment compliance and transplantation outcomes.This study aims to explore the psychological experiences of young patients with end stage renal disease during the waiting period for kidney transplantation, and provide a reference for formulating relevant psychological intervention measures.</p><p><strong>Methods: </strong>A descriptive qualitative research design was adopted. Using purposive sampling, 20 young ESRD patients awaiting for kidney transplantation at the Transplantation Center of Xiangya Third Hospital, Central South University, from June to August 2024, were recruited. Based on the socio-ecological systems theory, a semi-structured interview outline was developed, and directed content analysis was applied to analyze the interview data.</p><p><strong>Results: </strong>According to the results of qualitative interviews, 3 themes and 9 sub-themes were summarized as follows: Microsystem (disease pain experience, anxiety during transplantation waiting period, cognitive differentiation and coping differences), mesosystem (imbalance of family roles and dependent guilt, physician-patient trust dynamics, ambivalence toward peer support), and macrosystem (decision-making powerlessness caused by information asymmetry, sociocultural stigma and public bias, institutional dependence and passive behavior).</p><p><strong>Conclusions: </strong>Young ESRD patients experience complex psychological experiences during the waiting period for kidney transplantation. Healthcare providers should explore corresponding intervention measures based on patients' psychological status to improve their waiting period experience and promote both physical and mental health.</p>","PeriodicalId":39801,"journal":{"name":"中南大学学报(医学版)","volume":"50 5","pages":"888-896"},"PeriodicalIF":0.0,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12406099/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145016477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mechanism by which mechanical stimulation regulates chondrocyte apoptosis and matrix metabolism via primary cilia to delay osteoarthritis progression. 机械刺激通过初级纤毛调节软骨细胞凋亡和基质代谢延缓骨关节炎进展的机制。
Q3 Medicine Pub Date : 2025-05-28 DOI: 10.11817/j.issn.1672-7347.2025.250187
Huixian Ling, Sha Wu, Ziyu Luo, Yuyan Sun, Hongwei Shen, Haiqi Zhou, Yuanyuan Fu, Wen Wang, Thai Namanh Ngo, Ying Kong

Objectives: Osteoarthritis (OA) is one of the most common chronic degenerative diseases, with chondrocyte apoptosis and extracellular matrix (ECM) degradation as the major pathological changes. The mechanical stimulation can attenuate chondrocyte apoptosis and promote ECM synthesis, but the underlying molecular mechanisms remain unclear. This study aims to investigate the role of primary cilia (PC) in mediating the effects of mechanical stimulation on OA progression.

Methods: In vivo, conditional knockout mice lacking intraflagellar transport 88 (IFT88flox/flox IFT88 knockout; i.e., primary cilia-deficient mice) were generated, with wild-type mice as controls. OA models were established via anterior cruciate ligament transection combined with destabilization of the medial meniscus, followed by treadmill exercise intervention. OA progression was evaluated by hematoxylin-eosin staining, safranin O-fast green staining, and immunohistochemistry; apoptosis was assessed by TUNEL staining; and limb function by rotarod testing. In vitro, primary articular chondrocytes were isolated from mice and transfected with lentiviral vectors to suppress IFT88 expression, thereby constructing a primary cilia-deficient cell model. Interleukin-1β (IL-1β) was used to induce an inflammatory environment, while cyclic tensile strain (CTS) was applied via a cell stretcher to mimic mechanical loading on chondrocytes. Immunofluorescence and Western blotting were used to detect the protein expression levels of type II collagen α1 chain (COL2A1), primary cilia, IFT88, and caspase-12; reverse transcription polymerase chain reaction was performed to assess COL2A1 mRNA levels; and flow cytometry was used to evaluate apoptosis.

Results: In vivo, treadmill exercise significantly reduced Osteoarthritis Research Society International (OARSI) scores and apoptotic cell rates, and improved balance ability in wild-type OA mice, whereas IFT88-deficient OA mice showed no significant improvement. In vitro, CTS inhibited IL-1β-induced ECM degradation and apoptosis in primary chondrocytes; however, this protective effect was abolished in cells with suppressed primary cilia expression.

Conclusions: Mechanical stimulation delays OA progression by mediating signal transduction through primary cilia, thereby inhibiting cartilage degeneration and chondrocyte apoptosis.

目的:骨关节炎(Osteoarthritis, OA)是最常见的慢性退行性疾病之一,以软骨细胞凋亡和细胞外基质(extracellular matrix, ECM)降解为主要病理改变。机械刺激可减轻软骨细胞凋亡,促进ECM合成,但其分子机制尚不清楚。本研究旨在探讨初级纤毛(PC)在机械刺激对OA进展的介导作用。方法:在体内制备缺乏鞭毛内转运88的条件敲除小鼠(IFT88flox/flox IFT88敲除,即原代纤毛缺陷小鼠),野生型小鼠为对照。通过前交叉韧带横断联合内侧半月板失稳建立OA模型,然后进行跑步机运动干预。通过苏木精-伊红染色、红花素O-fast绿色染色和免疫组织化学评估OA进展;TUNEL染色检测细胞凋亡;并通过旋转杆测试四肢功能。体外分离小鼠原代关节软骨细胞,转染慢病毒载体抑制IFT88表达,构建原代纤毛缺失细胞模型。使用白细胞介素-1β (IL-1β)诱导炎症环境,而通过细胞拉伸器施加循环拉伸应变(CTS)来模拟软骨细胞的机械负荷。采用免疫荧光和Western blotting检测ⅱ型胶原α1链(COL2A1)、原毛、IFT88、caspase-12蛋白表达水平;逆转录聚合酶链反应检测COL2A1 mRNA水平;流式细胞术检测细胞凋亡。结果:在体内,跑步机运动显著降低骨关节炎国际研究学会(OARSI)评分和凋亡细胞率,并改善野生型OA小鼠的平衡能力,而ift88缺失的OA小鼠没有明显改善。在体外,CTS抑制il -1β诱导的ECM降解和原代软骨细胞凋亡;然而,这种保护作用在原始纤毛表达被抑制的细胞中被取消。结论:机械刺激通过介导初级纤毛的信号转导延缓OA的进展,从而抑制软骨退变和软骨细胞凋亡。
{"title":"Mechanism by which mechanical stimulation regulates chondrocyte apoptosis and matrix metabolism via primary cilia to delay osteoarthritis progression.","authors":"Huixian Ling, Sha Wu, Ziyu Luo, Yuyan Sun, Hongwei Shen, Haiqi Zhou, Yuanyuan Fu, Wen Wang, Thai Namanh Ngo, Ying Kong","doi":"10.11817/j.issn.1672-7347.2025.250187","DOIUrl":"10.11817/j.issn.1672-7347.2025.250187","url":null,"abstract":"<p><strong>Objectives: </strong>Osteoarthritis (OA) is one of the most common chronic degenerative diseases, with chondrocyte apoptosis and extracellular matrix (ECM) degradation as the major pathological changes. The mechanical stimulation can attenuate chondrocyte apoptosis and promote ECM synthesis, but the underlying molecular mechanisms remain unclear. This study aims to investigate the role of primary cilia (PC) in mediating the effects of mechanical stimulation on OA progression.</p><p><strong>Methods: </strong>In vivo, conditional knockout mice lacking intraflagellar transport 88 <i>(IFT88<sup>flox/flox</sup></i> IFT88 knockout; i.e., primary cilia-deficient mice) were generated, with wild-type mice as controls. OA models were established via anterior cruciate ligament transection combined with destabilization of the medial meniscus, followed by treadmill exercise intervention. OA progression was evaluated by hematoxylin-eosin staining, safranin O-fast green staining, and immunohistochemistry; apoptosis was assessed by TUNEL staining; and limb function by rotarod testing. In vitro, primary articular chondrocytes were isolated from mice and transfected with lentiviral vectors to suppress IFT88 expression, thereby constructing a primary cilia-deficient cell model. Interleukin-1β (IL-1β) was used to induce an inflammatory environment, while cyclic tensile strain (CTS) was applied via a cell stretcher to mimic mechanical loading on chondrocytes. Immunofluorescence and Western blotting were used to detect the protein expression levels of type II collagen α1 chain (COL2A1), primary cilia, IFT88, and caspase-12; reverse transcription polymerase chain reaction was performed to assess <i>COL2A1</i> mRNA levels; and flow cytometry was used to evaluate apoptosis.</p><p><strong>Results: </strong>In vivo, treadmill exercise significantly reduced Osteoarthritis Research Society International (OARSI) scores and apoptotic cell rates, and improved balance ability in wild-type OA mice, whereas IFT88-deficient OA mice showed no significant improvement. In vitro, CTS inhibited IL-1β-induced ECM degradation and apoptosis in primary chondrocytes; however, this protective effect was abolished in cells with suppressed primary cilia expression.</p><p><strong>Conclusions: </strong>Mechanical stimulation delays OA progression by mediating signal transduction through primary cilia, thereby inhibiting cartilage degeneration and chondrocyte apoptosis.</p>","PeriodicalId":39801,"journal":{"name":"中南大学学报(医学版)","volume":"50 5","pages":"864-875"},"PeriodicalIF":0.0,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12406113/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145016494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
中南大学学报(医学版)
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1